Stockreport

Eli Lilly's Donanemab Approval Heats Up Alzheimer's Disease Treatment Market | DelveInsight [Yahoo! Finance]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF This approval will intensify the competition between Eli Lilly's Donanemab and Biogen and Eisai's ADUHELM (aducanumab), and LEQEMBI (lecanemab). LAS VEGAS July 8, 2024 [Read more]